Breast DCE-MRI kinetic heterogeneity tumor markers: Preliminary associations with neoadjuvant chemotherapy response

Translational Oncology

Volumn 8, Issue 3, 2015, Pages 154-162

  Ashraf, Ahmed ^a   Gaonkar, Bilwaj ^a   Mies, Carolyn ^a   Demichele, Angela ^a   Rosen, Mark ^a   Davatzikos, Christos ^a   Kontos, Despina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; TUMOR MARKER;

ARTICLE; BIOPSY; BREAST CANCER; BREAST DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84930748541     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2015.03.005     Document Type: Article

References (48)

1. Loo CE, Teertstra HJ, Rodenhuis S, van de Viver DA, Hannemann J, Muller DA, Peteters MJ, and Gilhuijs KG (2008). Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol 191, 1331–1338.
2. Le-Petross HC and Hylton N (2010). Role of breast MR imaging in neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am 18(2), 249–258.
3. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg M, Robidoux A, Margolese R, Hoehn J, Vogel V, and Dakhil S, et al (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26, 778–785.
4. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani DA, and Zambetti M (1998). Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16, 93–100.
5. Bear HD, Anderson S, Brown A, Smith R, Mamounas E, Fisher B, Margolese R, Theoret H, Soran A, and Wickerham D, et al (2003). The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21, 4165–4174.
6. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, and Ford HT (1998). A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9, 1179–1184.
7. Smith IC, Heys SD, Hutcheon AW, Miller I, Payne S, Gilbert F, Ah-See A, Eremin O, Walker L, and Sarkar T, et al (2002). Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20, 1456–1466.
8. [8] Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, and George WD (2011). Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 21(1), 21–29.
9. [9] Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, and Darby S (2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 41, 162–177.
10. [10] Thoeny HC and Ross BD (2010). Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32(1), 2–16.
11. [11] Chen JH, Bahri S, Mehta RS, Kuzucan A, Yu HJ, Carpenter PM, Feig SA, Lin M, Hsiang DJ, and Lane KT, et al (2011). Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology 261(3), 735–743.
12. [12] McLaughlina R and Hylton N (2011). MRI in breast cancer therapy monitoring. NMR Biomed 24, 712–720.
13. [13] Arlinghaus LR, Li X, Levy M, Smith D, Welch EB, Gore JC, and Yankeelov TE (2010). Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J Oncol, 919620. http://dx.doi.org/10.1155/2010/919620.
14. [14] Therasse P, Arbuck SG, Eisenhauer EA, Wanders DA, Kaplan RS, Rubinstein DA, Verweij J, Glabbeke DA, van Oosterom ATAT, and Christian MC, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3), 205–216.
15. [15] Marinovich ML, Sardanelli DA, Ciatto S, Mamounas DA, Brennan M, Macaskill DA, Irwig L, von Minckwitz DA, and Houssami N (2012). Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast 21(5), 669–677.
16. [16] Ah-See MLW, Makris A, Taylor NJ, Harrison M, Richman P, Burcombe R, Stirling J, d’Arcy JA, Collins DJ, and Pittam MR, et al (2008). Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14(20), 6580–6589.
17. [17] Li X, Arlinghaus L, Ayers GD, Chakravarthy AB, Abramson DA, Abramson VG, Atuegwu N, Farley J, Mayer IA, and Kelley MC, et al (2014). DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med 71(4), 1592–1602.
18. [18] Etxano J, Insausti LP, Elizalde A, López-Vega DA, Plazaola A, and Martínez P (2014). Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy. Acta Radiol Oct 27. [pii: 0284185114556098, Epub ahead of print].
19. [19] Li X, Abramson RG, Arlinghaus LR, Kang H, Chakravarthy AB, Abramson DA, Farley J, Mayer DA, Kelley MC, and Meszoely DA, et al (2015). Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer. Invest Radiol 50(4), 195–204.
20. [20] Cha S, Yang L, Johnson G, Lai A, Chen MH, Tihan T, Wendland M, and Dillon (2006). Comparison of microvascular permeability measurements, Kt, determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. AJNR Am J Neuroradiol 27, 409–417.
21. [21] Tofts PS, Brix G, Buckly DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, N.A N.A.M. Parker GJ, et al (1999). Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10, 223–323.
22. [22] Hylton NM, Blume JD, Bernreuter WK, Pisano DA, Rosen MA, Morris DA, Weatherall PT, Lehman CD, Newstead GM, and Polin S, et al (2012). Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL. Radiology 263(3), 663–672.
23. [23] Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, and Macapinlac DA (2012). Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging—prospective assessment. Radiology 263(1), 53–63.
24. [24] Rieber A, Zeitler H, Rosenthal H, Gorich J, Kreienberg R, Brambs HJ, and Tomczak R (1997). MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 70(833), 452–458.
25. [25] Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, and Lu Y, et al (2001). MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8(6), 549–559.
26. [26] Park SH, Moon WK, Cho N, Song IC, Chang JM, Park IA, Han W, and Noh DY (2010). Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 257(1), 56–63.
27. [27] Marusyk A and Polyak K (2010). Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805(1), 105–117.
28. [28] Almendro V and Fuster G (2011). Heterogeneity of breast cancer: etiology and clinical relevance. Clin Transl Oncol 13, 767–773.
29. [29] Chen W, Giger ML, Lan L, and Bick U (2004). Computerized interpretation of breast mri: investigation of enhancement-variance dynamics. Med Phys 31, 1076–1082.
30. [30] Lee SH, Kim JH, Cho N, Park JS, Yang Z, Jung YS, and Moon WK (2010). Multilevel analysis of spatiotemporal association features for differentiation of tumor enhancement patterns in breast DCE-MRI. Med Phys 37.
31. [31] Zheng Y, Englander S, Baloch S, Zacharaki EI, Fan Y, Schnall MD, and Shen D (2009). STEP: spatiotemporal enhancement pattern for MR-based breast tumor diagnosis. Med Phys 37(7), 3192–3204.
32. [32] Agner S, Soman S, Libfeld E, McDonald M, Thomas K, Englander S, Rosen MA, Chin D, Nosher J, and Madabhushi A (2011). Textural kinetics: a novel dynamic contrast-enhanced (DCE)-MRI feature for breast lesion classification. J Digit Imaging 24(3), 446–463.
33. [33] Esserman LJ, Berry DA, Cheang MCU, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, and Lenburg DA, et al (2012). Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132(3), 1049–1062.
34. [34] Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Peeters DA, and Gilhuijs KG (2011). Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29, 660–666.
35. [35] Weinstein S and Rosen M (2010). Breast MR imaging: current indications and advanced imaging techniques. Radiol Clin North Am 48(5), 1013–1042.
36. Bhooshan N, Giger ML, Jansen SA, Li H, Lan L, and Newstead GM (2010). Cancerous breast lesions on DCE MR images: computerized characterization for image based prognostic markers. Radiology 254(3), 680–690.
37. [37] Loiselle CR, Eby PR, Peacock S, Kim JN, and Lehman CD (2011). Dynamic contrast-enhanced magnetic resonance imaging and invasive breast cancer: primary lesion kinetics correlated with axillary lymph node extracapsular extension. J Magn Reson Imaging 33(1), 96–101.
38. [38] Szabó BK, Aspelin P, Kristoffersen MW, Tot T, and Boné B (2003). Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol 13(11), 2425–2435.
39. [39] Tse GM, Chaiwun B, Wong KT, Yeung DK, Pang AL, Tang AP, and Cheung HS (2007). Magnetic resonance imaging of breast lesions—a pathologic correlation. Breast Cancer Res Treat 103(1), 1–10.
40. [40] Tozaki M (2004). Interpretation of breast MRI: correlation of kinetic and morphological parameters with pathological findings. Magn Reson Med Sci 3(4), 189–197.
41. [41] Ashraf AB, Daye D, Gavenonis S, Mies C, Feldman M, Rosen M, and Kontos D (2014). Identification of intrinsic imaging phenotypes for breast cancer tumors: Preliminary associations with gene expression profiles. Radiology 272(2), 374–384.
42. [42] Kass M, Witkin A, and Terzopoulos D (1988). Snakes: active contour models. Int J Comput Vis 1(4), 321–331.
43. [43] Hylton N (2006). MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am 14(3), 383–389.
44. [44] Lee SH, Kim JH, Cho N, Park JS, Yang Z, Jung YS, and Moon WK (2010). Multilevel analysis of spatiotemporal association features for differentiation of tumor enhancement patterns in breast DCE-MRI. Med Phys 37, 3940.
45. [45] Stojmenovic M and Nayak A (2007). Direct ellipse fitting and measuring based on shape boundaries. Proceedings of the 2nd Pacific Rim Conference on Advances in Image and Video Technology., PSIVT’07Berlin/Heidelberg, Germany: Springer-Verlag; 2007. p. 221–235.
46. [46] Chang RF, Wu WJ, Moon WK, and Chen DR (2005). Automatic ultrasound segmentation and morphology based diagnosis of solid breast tumors. Breast Cancer Res Treat 89(2), 179–185.
47. [47] Chen W, Giger ML, Bick U, and Newstead GM (2006). Automatic identification and classification of characteristic kinetic curves of breast lesions on DCE-MRI. Med Phys 33, 2878–2887.
48. [48] Partridge SC, Vanantwerp DA, Doot RK, Chai X, Kurland BF, Eby PR, Specht JM, Dunnwald LK, Schubert EK, and Lehman CD, et al (2010). Association between serial dynamic contrast-enhanced MRI and dynamic 8F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. J Magn Reson Imaging 32(5), 1124–1131.